BRIEF-NantKwest says FDA authorized co's IND for early-stage study

* NantKwest - U.S. FDA has authorized co's IND for its

first-in-human, high-affinity natural killer (haNK) cell therapy

Phase I clinical study

Source text for Eikon:

Further company coverage:

Read more